{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T00:06:08Z","timestamp":1758931568054,"version":"3.44.0"},"reference-count":24,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T00:00:00Z","timestamp":1758844800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.mdpi.com"],"crossmark-restriction":true},"short-container-title":["Medicina"],"abstract":"<jats:p>Background and Objectives: Hepatitis C virus (HCV) infection is highly prevalent among patients undergoing chronic hemodialysis in emerging countries and is associated with significant morbidity and mortality in this population. The objective of this study was to eradicate chronic HCV infection in patients undergoing chronic hemodialysis in Mauritania using a combination of sofosbuvir, 400 mg, and daclatasvir, 60 mg (direct acting antiviral\u2014DAA\u2014therapy), for 3 months. This was a prospective, single-arm, multicenter, interventional study. Materials and Methods: A total of 553 patients undergoing hemodialysis were screened for HCV across all hemodialysis centers nationwide. Biological parameters were compared before and after DAA therapy. Results: The prevalence of HCV infection was 6.8% (n = 38); two patients had undetectable HCV RNA. Out of the 36 eligible patients, 33 received DAA treatment. The median age of the patients was 49 (25\u201378) years. The average duration on hemodialysis was 9.4 (4\u201317) years. The median viral load before treatment was 538277 (10\u20134258571) IU\/L. The median alanine aminotransferase (ALT) level was 52.3 (14\u2013278) IU\/L. The median hemoglobin level was 10 (6\u201313) g\/dL. HCV viral load was undetectable at week 12 (W12) and week 24 (W24). The sustained virologic response (SVR) rate was 100%. Adverse events included one case of acute pancreatitis, six cases of fatigue (17%), five cases of headache (15%), four cases of diarrhea (12%), three cases of nausea (9%), and four cases of insomnia (12%). Conclusions: The combination of sofosbuvir and daclatasvir is effective in patients with HCV undergoing chronic hemodialysis, achieving a 100% SVR rate.<\/jats:p>","DOI":"10.3390\/medicina61101753","type":"journal-article","created":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T08:31:28Z","timestamp":1758875488000},"page":"1753","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The Effectiveness of a Sofosbuvir\/Daclatasvir Combination in the Treatment of HCV Infection in Patients from Mauritania Undergoing Chronic Hemodialysis"],"prefix":"10.3390","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9878-3896","authenticated-orcid":false,"given":"Sidi Mohamed","family":"Mah","sequence":"first","affiliation":[{"name":"Department of Nephrology, Hemodialysis and Renal Transplantation, National Hospital Center of Nouakchott, Nouakchott BP 612, Mauritania"},{"name":"Faculty of Medicine, Dentistry, and Pharmacy, University of Nouakchott, Nouakchott BP 803, Mauritania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soufiane","family":"Sid\u2019Ahmed","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Dentistry, and Pharmacy, University of Nouakchott, Nouakchott BP 803, Mauritania"},{"name":"Department of Infectious Diseases, National Hospital Center of Nouakchott, Nouakchott BP 612, Mauritania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed","family":"Lemrabott","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Hemodialysis and Renal Transplantation, National Hospital Center of Nouakchott, Nouakchott BP 612, Mauritania"},{"name":"Faculty of Medicine, Dentistry, and Pharmacy, University of Nouakchott, Nouakchott BP 803, Mauritania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Delahi","family":"Welli","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, National Hospital Center of Nouakchott, Nouakchott BP 612, Mauritania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jemal","family":"Awa","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Hemodialysis and Renal Transplantation, National Hospital Center of Nouakchott, Nouakchott BP 612, Mauritania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-4870-2080","authenticated-orcid":false,"given":"Abdellatif","family":"Sidi Aly","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Dentistry, and Pharmacy, University of Nouakchott, Nouakchott BP 803, Mauritania"},{"name":"National Council for Organ Donation and Transplantation, Nouakchott BP 557, Mauritania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5130-7286","authenticated-orcid":false,"given":"Lionel","family":"Rostaing","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Dialysis, Apheresis, and Kidney Transplantation, CHU Grenoble-Alpes, 38043 Grenoble, France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,9,26]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/j.kint.2018.11.038","article-title":"Prevalence, incidence, and risk factors for hepatitis C virus infection in hemodialysis patients","volume":"95","author":"Jadoul","year":"2019","journal-title":"Kidney Int."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"e0284169","DOI":"10.1371\/journal.pone.0284169","article-title":"Global epidemiology of hepatitis C virus in dialysis patients: A systematic review and meta-analysis","volume":"19","author":"Ngounoue","year":"2024","journal-title":"PLoS ONE"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1111\/jgh.14994","article-title":"The combination of sofosbuvir and daclatasvir is effective and safe in treating patients with hepatitis C and severe renal impairment","volume":"35","author":"Poustchi","year":"2020","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"3243","DOI":"10.1017\/S0950268817002242","article-title":"Epidemiology of hepatitis C virus among hemodialysis patients in the Middle East and North Africa: Systematic syntheses, meta-analyses, and meta-regressions","volume":"145","author":"Harfouche","year":"2017","journal-title":"Epidemiol. Infect."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"e0251570","DOI":"10.1371\/journal.pone.0251570","article-title":"The prevalence and associated factors of hepatitis B and C virus in hemodialysis patients in Africa: A systematic review and meta-analysis","volume":"16","author":"Adane","year":"2021","journal-title":"PLoS ONE"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"AASLD-IDSA HCV Guidance Panel (2018). Hepatitis C Hepatitis C Guidance 2018 Update: AASLD-IDSA recommendations for testing, managing, and treating hepatitis C virus infection. Clin. Infect. Dis., 67, 1477\u20131492.","DOI":"10.1093\/cid\/ciy585"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jhep.2016.02.044","article-title":"Pharmacokinetics, safety and efficacy of a full dose sofosbuvir-based regimen given daily in hemodialysis patients with chronic hepatitis C","volume":"65","author":"Desnoyer","year":"2016","journal-title":"J. Hepatol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.eimc.2017.10.012","article-title":"Sofosbuvir plus daclatasvir as an alternative for patients on haemodialysis with genotype 2 hepatitis C virus infection","volume":"36","author":"Padilla","year":"2018","journal-title":"Enfermedades Infecc. Microbiol. Clin. Engl. Ed."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"9180","DOI":"10.1038\/s41598-020-66182-8","article-title":"Elbasvir\/grazoprevir for hepatitis C virus genotype 1b East-Asian patients receiving hemodialysis","volume":"10","author":"Liu","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1002\/jmv.27374","article-title":"Safery and efficacy of grazoprevir\/elbasvir in the treatment of acute hepatitis C in hemodialysis patients","volume":"94","author":"Ji","year":"2022","journal-title":"J. Med. Virol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1111\/hepr.13482","article-title":"Clinical outcomes of hepatitis C virus elimination using glecaprevir and pibrentasvir in hemodialysis patients: A multicenter study","volume":"50","author":"Morishita","year":"2020","journal-title":"Hepatol. Res."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"e458","DOI":"10.1002\/hsr2.458","article-title":"Safety and efficacy of glecaprevir and pibrentasvir in north Tohoku Japanese patients with genotype \u00bd hepatitis C virus infection","volume":"5","author":"Miyasaka","year":"2022","journal-title":"Health Sci. Rep."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e13884","DOI":"10.1111\/cts.13884","article-title":"Pharmacokinetics of Sofosbuvir\/Velpatasvir and efficacy of an alternate-day treatment in hemodialysis patients with chronic hepatitis C infection","volume":"17","author":"Chariyavilaskul","year":"2024","journal-title":"Clin. Transl. Sci."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"14332","DOI":"10.1038\/s41598-020-71205-5","article-title":"Efficacy and safety of sofosbuvir in the treatment of hep C among patients on hemodialysis: A systematic review and meta-analysis","volume":"10","author":"Shehadeh","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1111\/jvh.12553","article-title":"Pharmacokinetics, efficacy and safety of daclatasvir plus asunaprevir in dialysis patients with chronic hepatitis C: Pilot study","volume":"23","author":"Kawakami","year":"2016","journal-title":"J. Viral Hepat."},{"key":"ref_16","first-page":"e15932","article-title":"Direct-Acting Antivirals in the Treatment of Hepatitis C Virus (HCV)\/Human Immunodeficiency Virus (HIV) Co-infected Patients: Real-Life Experience From Nepal","volume":"13","author":"Kc","year":"2021","journal-title":"Cureus"},{"key":"ref_17","first-page":"438","article-title":"Real-world direct-acting antiviral treatment in kidney transplant and hemodialysis patients: The EpiTer-2 multicenter observational study","volume":"34","author":"Tronina","year":"2021","journal-title":"Ann Gastroenterol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.29271\/jcpsp.2020.11.1230","article-title":"Sofosbuvir-based Treatment for HCV: A Safe Option in Patients Undergoing Hemodialysis","volume":"30","author":"Salim","year":"2020","journal-title":"J. Coll. Physicians Surg. Pak."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1002\/(SICI)1096-9071(199906)58:2<139::AID-JMV7>3.0.CO;2-7","article-title":"Molecular evidence for nosocomial transmission of hepatitis C virus in a French hemodialysis unit","volume":"58","author":"Izopet","year":"1999","journal-title":"J. Med. Virol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1002\/jmv.20877","article-title":"Determining the source of nosocomial transmission in hemodialysis units in Tunisia by sequencing NS5B and E2 sequences of HCV","volume":"79","author":"Dubois","year":"2007","journal-title":"J. Med. Virol."},{"key":"ref_21","first-page":"286","article-title":"Association of anti-HCV sero-prevalence with blood transfusion and practice of haemodialysis from multiple centres in patients on maintenance haemodialysis","volume":"36","author":"Amjad","year":"2020","journal-title":"Pak. J. Med. Sci."},{"key":"ref_22","first-page":"2429","article-title":"FORMOSA-LIKE investigators. Therapy as prevention toward HCV elimination in maintenance hemodialysis: A multi-center, prospective cohort study","volume":"16","author":"Huang","year":"2023","journal-title":"Clin. Kidney J."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"112","DOI":"10.55133\/eji.310212","article-title":"The burden of HCV among prevalent hemodialysis patients after the National Egyptian HCV Eradication program","volume":"31","author":"Sarhan","year":"2024","journal-title":"Egypt. J. Immunol."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Gomaa, A., Gomaa, M., Allam, N., and Waked, I. (2024). Hepatitis C elimination in Egypt: Story of success. Pathogens, 13.","DOI":"10.3390\/pathogens13080681"}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/61\/10\/1753\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T09:05:13Z","timestamp":1758877513000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/61\/10\/1753"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,26]]},"references-count":24,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,10]]}},"alternative-id":["medicina61101753"],"URL":"https:\/\/doi.org\/10.3390\/medicina61101753","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,26]]}}}